Largest pharmaceutical companies in the United States by revenue
Everything the company sold in its latest fiscal year, before any cost is taken off.
Johnson & Johnson leads the 36 pharmaceutical companies in the United States ranked by revenue, at SAR 353.4B, ahead of Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B). Figures as of 20 Nov 2026, 22:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 36
- First
- Johnson & JohnsonSAR 353.4B
- Median
- SAR 5.2B
- Combined market value
- SAR 14.01T
- Countries
- 1
- Not ranked
- 8no revenue on file
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Revenue ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Johnson & JohnsonJNJ · Health Care | SAR 353.4B | SAR 2.44T | SAR 1,014.67 | 1.25% up | 31% up | ||
| 2 | Eli LillyLLY · Health Care | SAR 244.5B | SAR 4.5T | SAR 5,053.68 | 0.30% down | 28% up | ||
| 3 | Merck & CoMRK · Health Care | SAR 243.9B | SAR 1.24T | SAR 501.65 | 0.69% up | 36% up | ||
| 4 | PfizerPFE · Health Care | SAR 234.8B | SAR 585.9B | SAR 102.79 | 0.51% down | 10% up | ||
| 5 | AbbVieABBV · Health Care | SAR 229.4B | SAR 1.9T | SAR 1,073.68 | 0.94% up | 20% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | SAR 180.8B | SAR 450.9B | SAR 220.59 | 0.79% up | 26% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | SAR 166.3B | SAR 669.2B | SAR 386.40 | 0.84% down | 19% down | ||
| 8 | Regeneron PharmaceuticalsREGN · Health Care | SAR 53.8B | SAR 357.3B | SAR 3,453.97 | 0.19% down | 22% up | ||
| 9 | ViatrisVTRS · Health Care | SAR 53.6B | SAR 84.4B | SAR 73.64 | 1.26% down | 90% up | ||
| 10 | Vertex PharmaceuticalsVRTX · Health Care | SAR 45B | SAR 489.9B | SAR 1,932.10 | 1.08% down | 22% up | ||
| 11 | ZoetisZTS · Health Care | SAR 35.5B | SAR 120.6B | SAR 296.78 | 2.08% down | 34% down | ||
| 12 | Elanco Animal HealthELAN · Health Care | SAR 17.7B | SAR 48.3B | SAR 96.56 | 2.09% down | 18% up | ||
| 13 | Alnylam PharmaceuticalsALNY · Health Care | SAR 13.9B | SAR 72.3B | SAR 539.54 | 2.71% down | 66% down | ||
| 14 | BioMarin PharmaceuticalBMRN · Health Care | SAR 12.1B | SAR 43.9B | SAR 226.63 | 1.64% down | 12% up | ||
| 15 | United TherapeuticsUTHR · Health Care | SAR 11.9B | SAR 88.6B | SAR 2,081.07 | 0.78% down | 18% up | ||
| 16 | Amneal PharmaceuticalsAMRX · Health Care | SAR 11.3B | SAR 27.6B | SAR 79.23 | 1.26% down | 79% up | ||
| 17 | Royalty PharmaRPRX · Health Care | SAR 8.9B | SAR 147.7B | SAR 256.79 | 1.08% up | 74% up | ||
| 18 | PTC TherapeuticsPTCT · Health Care | SAR 6.5B | SAR 17.7B | SAR 211.66 | 3.27% down | 26% down | ||
| 19 | Legend BiotechLEGN · Health Care | SAR 3.9B | SAR 11.1B | SAR 57.21 | 5.28% down | 43% down | ||
| 20 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 3.6B | SAR 33B | SAR 1,422.19 | 4.45% down | 28% down | ||
| 21 | Ionis PharmaceuticalsIONS · Health Care | SAR 3.5B | SAR 16.6B | SAR 99.71 | 2.35% down | 64% down | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 3.1B | SAR 21.9B | SAR 155.20 | 5.22% down | 8% up | ||
| 23 | Corcept TherapeuticsCORT · Health Care | SAR 2.9B | SAR 26.1B | SAR 238.67 | 2.09% down | 16% down | ||
| 24 | Axsome TherapeuticsAXSM · Health Care | SAR 2.4B | SAR 25.5B | SAR 485.29 | 4.66% down | 9% down | ||
| 25 | TG TherapeuticsTGTX · Health Care | SAR 2.3B | SAR 35.9B | SAR 237.62 | 2.37% down | 103% up | ||
| 26 | InsmedINSM · Health Care | SAR 2.3B | SAR 116.3B | SAR 530.20 | 2.17% down | 27% down | ||
| 27 | Mirum PharmaceuticalsMIRM · Health Care | SAR 2B | SAR 23.5B | SAR 360.63 | 0.65% up | 35% up | ||
| 28 | BridgeBio PharmaBBIO · Health Care | SAR 1.9B | SAR 55.6B | SAR 285.23 | 2.75% down | 15% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | SAR 1.8B | SAR 16.9B | SAR 176.32 | 2.69% down | 39% up | ||
| 30 | Ligand PharmaceuticalsLGND · Health Care | SAR 1B | SAR 21.5B | SAR 1,076.12 | 0.03% down | 44% up | ||
| 31 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 711.9M | SAR 29.2B | SAR 421.52 | 3.80% down | 15% up | ||
| 32 | CytokineticsCYTK · Health Care | SAR 330.3M | SAR 26.5B | SAR 190.50 | 1.32% down | 21% down | ||
| 33 | Protagonist TherapeuticsPTGX · Health Care | SAR 172.6M | SAR 29.7B | SAR 455.43 | 2.11% down | 45% up | ||
| 34 | Dianthus TherapeuticsDNTH · Health Care | SAR 7.6M | SAR 17.9B | SAR 317.19 | 0.33% down | 105% up | ||
| 35 | Spyre TherapeuticsSYRE · Health Care | SAR 0 | SAR 33.3B | SAR 350.65 | 4.26% down | 302% up | ||
| 36 | Praxis Precision MedicinesPRAX · Health Care | SAR 0 | SAR 31.5B | SAR 1,127.06 | 3.37% down | 83% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Revenue is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7515 SAR). 8 companies have no revenue on file and are not ranked here.
Questions and answers
Which pharmaceutical companies in the United States rank first by revenue?
Johnson & Johnson (SAR 353.4B), Eli Lilly (SAR 244.5B) and Merck & Co (SAR 243.9B) are the top three of the 36 pharmaceutical companies in the United States ranked by revenue as of 20 Nov 2026, 22:41 UTC.
How many pharmaceutical companies in the United States are in this ranking?
36 are ranked by revenue. 8 more have no revenue on file and are left out rather than ranked at zero.
What are these pharmaceutical companies in the United States worth together?
The 36 pharmaceutical companies in the United States ranked by revenue have a combined market value of SAR 14.01T as of 20 Nov 2026, 22:41 UTC.
What does ranking by revenue measure?
Everything the company sold in its latest fiscal year, before any cost is taken off.
Learn how this ranking works
All markets guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
- How companies are sorted into sectors and industries
Companies are sorted into sectors and industries by classification systems. The index providers MSCI and S&P Dow Jones Indices use GICS: 11 sectors split into 25 industry groups, 74 industries and 163 sub-industries. SEC filings carry a four-digit SIC code. The two can place one company differently, because each looks at the business from its own angle.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by revenue”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=revenue
Underlying data: Yahoo Finance; SEC EDGAR.